Aurinia Pharmaceuticals Inc.
AUPH
$0.10
Change (1 day)
$10.05
Year High
$4.71
Year Low
Categories
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.
Aurinia Pharmaceuticals Inc. (AUPH) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 24.09 M | 48.73 M | 170.11 M | 548.06 M | 424.8 M |
| 2022 | 13.48 M | -86,084,000 | 65.43 M | 470.86 M | 442.54 M |
| 2021 | 15.41 M | -223,161,000 | 64.28 M | 543.37 M | 513.32 M |
| 2020 | 1.02 M | -263,943,000 | 55.91 M | 463.66 M | 419.43 M |
| 2019 | 368 K | -306,019,000 | 53.17 M | 326.68 M | 315.14 M |